Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

p21/WAFl À¯ÀüÀÚÀÇ Àü´ÞÀÌ ÀÎü ½ÅÀå¾Ï°ú ¹æ±¤¾Ï ¼¼Æ÷ÁÖ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ¿¬±¸ The Effect of Transfer of p21/WAF1 Gene on Kidney and Bladder Cancer Cell Lines

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 2È£ p.175 ~ 186
¹æÀåÈ£, ±è¿ë±Ô,
¼Ò¼Ó »ó¼¼Á¤º¸
¹æÀåÈ£ (  ) 
Áß¾Ó´ëÇб³ ´ëÇпø °£È£Çаú

±è¿ë±Ô (  ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

°á·Ð
ÀÎüÀÇ ½ÅÀå¾Ï(CURC1, CURC2)°ú ¹æ±¤¾Ï(T24, RT4) ¹× °£¾Ï(Hep3b, HepG2) ¼¼Æ÷ÁÖ¸¦
´ë»óÀ¸·Î p21/WAF1 À¯ÀüÀÚ¸¦ Åõ¿©ÇÏ¿© ±× Ç×¾ÏÈ¿°ú¿Í ÀÛ¿ë±âÀüÀ» ¿¬±¸ÇÏ¿´´Ù. ÀÎüÆó¾Ï¼¼
Æ÷ÁַκÎÅÍ RT-PCR¹æ¹ýÀ» ÀÌ¿ëÇÏ¿© ÀÎüÀÇ Á¤»ó P21/WAF1À¯ÀüÀÚÀÇ Àüü cDNA¸¦
cloningÇÏ¿´À¸¸ç, À̸¦ pCMV Çö󽺹̵忡 »ðÀÔÇÏ¿© pCMV-p21º¤Å͸¦ ÇÕ¼ºÇÏ¿´À¸¸ç À̸¦
HDL¾çÀ̿¼º ¸®Æ÷¼Ø°ú °áÇÕÇÏ¿© °¢ ¼¼Æ÷ÁÖ¿¡ Åõ¿©ÇÏ¿©, »ýÁ¸¼¼Æ÷¼ö¸¦ ÃøÁ¤ÇÏ°í p21/WAF1
ÀÇ ¹ßÇöÀ» RT-PCR·Î °Ë»öÇÏ¿´À¸¸ç, ¼¼Æ÷ÁÖ±âÀÇ º¯È­¿Í °í»ç¹ß»ý ¿©ºÎ¸¦ ¿¬±¸ÇÏ¿´´Ù. ±×
°á°ú 1) pCMVÇÃ¶ó½º¹Ì µå¿Í HDLÀÇ °áÇÕü°¡ À¯ÀüÀÚ Àü´Þ ¹× ¹ßÇö È¿À²ÀÌ ¶Ù¾î³²À» È®ÀÎ
ÇÏ¿´°í, 2) p53ÀÇ µ¹¿¬º¯ÀÌ´Â p21/WAFlÀÇ ¹ßÇö°ú ±íÀº ¿¬°üÀÌ ÀÖÀ¸¸ç, p53ÀÇ µ¹¿¬º¯ÀÌ°¡
¾ø´Â ¾Ï¼¼Æ÷ÁÖ¿¡¼­´Â p21/WAF1°¡ ¹ßÇöµÇ³ª p53ÀÇ µ¹¿¬º¯ÀÌ°¡ ÀÖÀ» ¶§´Â p21/WAF1ÀÇ ¹ß
ÇöÀÌ ÇöÀúÈ÷ °¨¼ÒµÇ¾î ÀÖÀ½À» ¾Ë ¼ö ÀÖ¾úÀ¸¸ç, 3) p21/WAF1 À¯ÀüÀÚ Ä¡·á´Â p53ÀÇ µ¹¿¬º¯
ÀÌ ¿©ºÎ³ª ¹«Ã³Ä¡ »óÅ¿¡¼­ÀÇ p21/WAFl¹ßÇö Á¤µµ¿Í »ó°ü¾øÀÌ ½ÅÀå¾Ï°ú ¹æ±¤¾Ï¼¼Æ÷ ¹× °£
¾Ï¼¼Æ÷¿¡ ´ëÇØ ¸ðµÎ À¯ÀÇÇÏ°Ô Áõ½ÄÀ» ¾ïÁ¦ÇÔÀ» È®ÀÎÇÏ¿´°í, 4) p21/WAF1 À¯ÀüÀÚÅõ¿©°¡ ½Å
Àå¾Ï°ú ¹æ±¤¾Ï¼¼Æ÷¿¡ °í»ç¸¦ À¯¹ßÇÔÀ» ¹ß°ßÇÏ¿©, p21/WAF1 À¯ÀüÀÚ°¡ ¾Ï¼¼Æ÷ÁÖ±âÀÇ ÁøÇàÀ»
¾ïÁ¦ÇϹǷμ­ Áõ½ÄÀ» ¾ïÁ¦ÇÑ´Ù´Â ±âÁ¸ÀÇ Çм³¿¡ Ãß°¡·Î °í»ç¸¦ À¯¹ßÇÏ´Â ±â´Éµµ ÀÖÀ½À» ¾Ë
¼ö ÀÖ¾ú´Ù.

Purpose : To identify antitumor effect, indication and antitumor mechanism of
p21/WAF1 gene therapy in human kidney and bladder cancer.
Materials and Methods : We cloned cDNA of wild type human p21 gene by reverse
transcription-polymerase chain reaction(RT-PCR) technology and constructed a
mammalian expression plasmid vector carrying cDNA of wild type human p21 and CMV
enhancer/promotor(pCMV-p2l). pCMV-p2l was administered in vitro in complex with
HDL cationic polyliposome into human kidney cancer cells(CURC-1 and CURC-2),
bladder cancer cells(RT4 and T24), and liver cancer cells(Hep3B and HepG2), followed
by analysis of viable cell number, cellular morphology, cell cycle distribution and
development of apoptosis.
Results : The expression of p21 was preserved in p53-wild type cells and markedly
decreased or absent in p53-mutant cells. Administration of pCMV-p21 :HDL complex
induced high level expression of p21 and significant suppression of growth in all of the
cancer cells examined, regardless of their genetic status of p21 and p53. Transfer of p21
to cancer cells induced not only decrease of proportion of cells in G2+M/S phase but
also apoptosis.
Conclusions : HDL cationic polyliposome-mediated p21 gene transfer may become a
promising therapeutic modality for human kidney and bladder cancer and that p21 may
have a novel function to induce apoptosis to human bladder and kidney cancer cells.
Further studies are necessary on in vivo antitumor effect of p21 gene transfer and
molecular mechanism of p21 gene-induced apoptosis.

Å°¿öµå

p21/WAF1; Gene transfer; Kidney cancer; Bladder cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS